LUC00218I2 - - Google Patents

Download PDF

Info

Publication number
LUC00218I2
LUC00218I2 LU00218C LUC00218C LUC00218I2 LU C00218 I2 LUC00218 I2 LU C00218I2 LU 00218 C LU00218 C LU 00218C LU C00218 C LUC00218 C LU C00218C LU C00218 I2 LUC00218 I2 LU C00218I2
Authority
LU
Luxembourg
Application number
LU00218C
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of LUC00218I2 publication Critical patent/LUC00218I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU00218C 2013-12-27 2021-08-18 LUC00218I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361921181P 2013-12-27 2013-12-27
US201461937838P 2014-02-10 2014-02-10
EP14874374.3A EP3087184B1 (fr) 2013-12-27 2014-12-26 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire
PCT/US2014/072410 WO2015100436A1 (fr) 2013-12-27 2014-12-26 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire

Publications (1)

Publication Number Publication Date
LUC00218I2 true LUC00218I2 (fr) 2022-10-07

Family

ID=53479713

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00218C LUC00218I2 (fr) 2013-12-27 2021-08-18

Country Status (21)

Country Link
US (7) US9701966B2 (fr)
EP (3) EP3087184B1 (fr)
JP (2) JP6886818B2 (fr)
AU (2) AU2014369850B2 (fr)
CA (1) CA2935220A1 (fr)
CY (2) CY1124203T1 (fr)
DK (2) DK3581654T3 (fr)
ES (2) ES2875558T3 (fr)
FI (1) FIC20210025I1 (fr)
FR (1) FR21C1044I2 (fr)
HR (1) HRP20210612T1 (fr)
HU (2) HUE055470T2 (fr)
LT (2) LT3581654T (fr)
LU (1) LUC00218I2 (fr)
NO (1) NO2021038I1 (fr)
PL (1) PL3581654T3 (fr)
PT (1) PT3581654T (fr)
RS (1) RS61892B1 (fr)
SI (1) SI3581654T1 (fr)
SM (1) SMT202100325T1 (fr)
WO (1) WO2015100436A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
SI3581654T1 (sl) * 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
TWI864340B (zh) * 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016205323A1 (fr) * 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant l'hydroxyacide oxydase (glycolate oxydase, hao1) et procédés d'utilisation de ceux-ci
EP3522719A1 (fr) * 2016-10-05 2019-08-14 Syngenta Participations AG Procédés de conservation de l'activité biologique d'acides ribonucléiques
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
AU2018301829B2 (en) 2017-07-13 2024-08-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
MX2021001070A (es) * 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
EP3898661A1 (fr) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Modification génétique du gène de l'hydroxyacide oxydase 1 pour le traitement de l'hyperoxalurie primaire
WO2021086874A1 (fr) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Carboxylates hétérocycles en tant qu'inhibiteurs de glycolate oxydase
WO2021237067A1 (fr) * 2020-05-22 2021-11-25 President And Fellows Of Harvard College Duplex oligonucléotidiques induisant l'interféron et méthodes d'utilisation
KR20250099412A (ko) 2020-11-12 2025-07-01 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
EP4043018A1 (fr) 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition et procédé pour réduire les niveaux d'oxalate chez des patients en dialyse d'entretien
KR20240034746A (ko) * 2021-06-04 2024-03-14 아버 바이오테크놀로지스, 인크. 하이드록시산 산화효소 1(hao1)을 표적으로 하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
JP2024528659A (ja) * 2021-07-19 2024-07-30 アルナイラム ファーマシューティカルズ, インコーポレイテッド 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
CN117041337A (zh) * 2023-08-14 2023-11-10 中国电信股份有限公司技术创新中心 网络流量的处理方法、系统以及risc装置
EP4725949A1 (fr) * 2024-10-08 2026-04-15 BioSpring Gesellschaft für Biotechnologie mbH Synthese amelioree en phase solide de phosphoramidites de molecules oligonucleotidiques longues

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513207A (en) 1894-01-23 Rail-brake
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
EP1253199A1 (fr) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Acide nucléique enzymatique contenant des résidues abasiques
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US7678897B2 (en) * 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
EP2305813A3 (fr) 2002-11-14 2012-03-28 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (fr) 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2559955C (fr) 2004-03-15 2016-02-16 City Of Hope Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin
CA2566286A1 (fr) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide provoquant l'interference rna et procede de regulation d'expression genetique avec l'usage de ce dernier
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (fr) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification de molecules d'acide ribonucleique bicatenaire
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
DE102007021853A1 (de) 2007-05-10 2008-11-13 Norma Germany Gmbh Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh) 2008-12-08 2012-06-20 鸿富锦精密工业(深圳)有限公司 光伏电池
KR20110110776A (ko) * 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
EP2756845B1 (fr) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Procédés et compositions pour l'inhibition spécifique de KRAS par de l'ARN double brin asymétrique
WO2010135682A1 (fr) * 2009-05-21 2010-11-25 Institute For Systems Biology Nouveaux biomarqueurs pour lésion du foie
UA118649C2 (uk) 2011-11-18 2019-02-25 Елнілем Фармасьютікалз, Інк. ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
SI3581654T1 (sl) * 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
TWI864340B (zh) * 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法

Also Published As

Publication number Publication date
FR21C1044I2 (fr) 2022-09-23
EP3581654B1 (fr) 2021-03-31
EP3087184A1 (fr) 2016-11-02
JP2020036603A (ja) 2020-03-12
SMT202100325T1 (it) 2021-07-12
FIC20210025I1 (fi) 2021-08-25
CY2021022I2 (el) 2021-12-31
EP3581654A1 (fr) 2019-12-18
AU2021201953A1 (en) 2021-04-29
RS61892B1 (sr) 2021-06-30
EP3087184A4 (fr) 2017-08-16
HUS2100041I1 (hu) 2021-10-28
US10435692B2 (en) 2019-10-08
JP7109416B2 (ja) 2022-07-29
US20150184160A1 (en) 2015-07-02
US20180291379A1 (en) 2018-10-11
US9701966B2 (en) 2017-07-11
JP6886818B2 (ja) 2021-06-16
CA2935220A1 (fr) 2015-07-02
HUE055470T2 (hu) 2021-11-29
DK3087184T3 (da) 2019-07-29
FR21C1044I1 (fr) 2021-11-19
PL3581654T3 (pl) 2021-09-13
US20200002705A1 (en) 2020-01-02
ES2875558T3 (es) 2021-11-10
ES2749855T3 (es) 2020-03-24
LTPA2021008I1 (fr) 2021-09-27
EP3087184B1 (fr) 2019-07-03
EP3892727A1 (fr) 2021-10-13
AU2014369850A1 (en) 2016-07-14
US20170306333A1 (en) 2017-10-26
US10487330B2 (en) 2019-11-26
NO2021038I1 (no) 2021-09-16
US20190211340A1 (en) 2019-07-11
LTC3581654I2 (fr) 2023-07-10
HRP20210612T1 (hr) 2021-08-20
CY2021022I1 (el) 2021-12-31
US10465195B2 (en) 2019-11-05
US11873493B2 (en) 2024-01-16
US20210230604A1 (en) 2021-07-29
JP2017502668A (ja) 2017-01-26
LT3581654T (lt) 2021-06-25
US11060093B2 (en) 2021-07-13
DK3581654T3 (da) 2021-04-26
AU2014369850B2 (en) 2021-04-08
WO2015100436A1 (fr) 2015-07-02
PT3581654T (pt) 2021-06-02
US9828606B2 (en) 2017-11-28
US20190194665A1 (en) 2019-06-27
CY1124203T1 (el) 2021-12-31
SI3581654T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
FR21C1044I1 (fr)
AP2016009275A0 (fr)
BR112015007533A2 (fr)
BR102016010778A2 (fr)
BR112014017733A2 (fr)
BR112014017739A2 (fr)
BR112016000999A2 (fr)
BR112014018502A2 (fr)
BR112014019326A2 (fr)
BR112014018516A2 (fr)
BR112014017765A2 (fr)
BR112014018480A2 (fr)
BR112014017855A2 (fr)
BR112014020341A2 (fr)
BR112014017669A2 (fr)
BR112016001155A2 (fr)
BR112014018207A2 (fr)
BR112016008594A2 (fr)
BR112014017901A2 (fr)
BR112014018483A2 (fr)
BR112014017722A2 (fr)
BR112014017794A2 (fr)
BR112014018578A2 (fr)
BR112014017601A2 (fr)
BR112015015312A2 (fr)